565 related articles for article (PubMed ID: 11801468)
21. Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD.
Levine JE; Wiley J; Kletzel M; Yanik G; Hutchinson RJ; Koehler M; Neudorf S
Bone Marrow Transplant; 2000 Jan; 25(1):13-8. PubMed ID: 10654008
[TBL] [Abstract][Full Text] [Related]
22. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
Hartwig UF; Winkelmann N; Wehler T; Kreiter S; Schneider PM; Meyer RG; Ullmann AJ; Huber C; Kolbe K; Herr W
Ann Hematol; 2005 May; 84(5):331-8. PubMed ID: 15726363
[TBL] [Abstract][Full Text] [Related]
23. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome.
Montero A; Savani BN; Shenoy A; Read EJ; Carter CS; Leitman SF; Mielke S; Rezvani K; Childs R; Barrett AJ
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1318-25. PubMed ID: 17162214
[TBL] [Abstract][Full Text] [Related]
24. Nonmyeloablative stem cell transplantation with CD8-depleted or CD34-selected peripheral blood stem cells.
Baron F; Baudoux E; Frère P; Tourqui S; Schaaf-Lafontaine N; Greimers R; Herens C; Fillet G; Beguin Y
J Hematother Stem Cell Res; 2002 Apr; 11(2):301-14. PubMed ID: 11983101
[TBL] [Abstract][Full Text] [Related]
25. Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia.
Kobbe G; Fenk R; Neumann F; Bernhardt A; Steidl U; Kondakci M; Graef T; Aivado M; Vaupel M; Huenerlituerkoglu AN; Kronenwett R; Pape H; Hildebrand B; Germing U; Haas R
Cytotherapy; 2004; 6(6):533-42. PubMed ID: 15764020
[TBL] [Abstract][Full Text] [Related]
26. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children.
Kałwak K; Porwolik J; Mielcarek M; Gorczyńska E; Owoc-Lempach J; Ussowicz M; Dyla A; Musiał J; Paździor D; Turkiewicz D; Chybicka A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1388-401. PubMed ID: 20382248
[TBL] [Abstract][Full Text] [Related]
27. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies.
Cao TM; Wong RM; Sheehan K; Laport GG; Stockerl-Goldstein KE; Johnston LJ; Shizuru JA; Negrin RS; Lowsky R
Exp Hematol; 2005 Mar; 33(3):279-85. PubMed ID: 15730851
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic peripheral blood stem cell transplantation for haematological malignancies--an analysis of kinetics of engraftment and GVHD risk.
Miflin G; Russell NH; Hutchinson RM; Morgan G; Potter M; Pagliuca A; Marsh J; Bell A; Milligan D; Lumley M; Cook G; Franklin I
Bone Marrow Transplant; 1997 Jan; 19(1):9-13. PubMed ID: 9012925
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. allo-PBPCT Spanish Group.
Urbano-Ispizua A; Solano C; Brunet S; Hernández F; Sanz G; Alegre A; Petit J; Besalduch J; Vivancos P; Díaz MA; Moraleda JM; Carreras E; Ojeda E; de la Rubia J; Benet I; Domingo-Albós A; García-Conde J; Rozman C
Bone Marrow Transplant; 1996 Jul; 18(1):35-40. PubMed ID: 8831993
[TBL] [Abstract][Full Text] [Related]
30. Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose.
Min CK; Kim DW; Lee JW; Han CW; Min WS; Kim CC
Haematologica; 2001 Mar; 86(3):303-10. PubMed ID: 11255278
[TBL] [Abstract][Full Text] [Related]
31. Retrospective comparison of CD34-selected allogeneic peripheral blood stem cell transplantation followed by CD8-depleted donor lymphocyte infusions with unmanipulated bone marrow transplantation.
Baron F; Baudoux E; Fillet G; Beguin Y
Hematology; 2002 Jun; 7(3):137-43. PubMed ID: 12243975
[TBL] [Abstract][Full Text] [Related]
32. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.
de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D
Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440
[TBL] [Abstract][Full Text] [Related]
33. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity.
Bethge WA; Haegele M; Faul C; Lang P; Schumm M; Bornhauser M; Handgretinger R; Kanz L
Exp Hematol; 2006 Dec; 34(12):1746-52. PubMed ID: 17157172
[TBL] [Abstract][Full Text] [Related]
34. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study.
Lewalle P; Triffet A; Delforge A; Crombez P; Selleslag D; De Muynck H; Bron D; Martiat P
Bone Marrow Transplant; 2003 Jan; 31(1):39-44. PubMed ID: 12621505
[TBL] [Abstract][Full Text] [Related]
35. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation.
Solomon SR; Nakamura R; Read EJ; Leitman SF; Carter C; Childs R; Dunbar CE; Young NS; Barrett AJ
Bone Marrow Transplant; 2003 May; 31(9):783-8. PubMed ID: 12732885
[TBL] [Abstract][Full Text] [Related]
36. T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation.
Baron F; Schaaf-Lafontaine N; Humblet-Baron S; Meuris N; Castermans E; Baudoux E; Frère P; Bours V; Fillet G; Beguin Y
Transplantation; 2003 Dec; 76(12):1705-13. PubMed ID: 14688520
[TBL] [Abstract][Full Text] [Related]
37. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
[TBL] [Abstract][Full Text] [Related]
38. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
39. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
[TBL] [Abstract][Full Text] [Related]
40. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Wang JZ; Gao ZY; Zhang YC; Jiang Q; Shi HX; Lu DP
Bone Marrow Transplant; 2006 Aug; 38(4):291-7. PubMed ID: 16883312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]